Cover Image
市場調查報告書

麥角生物鹼(用作偏頭痛治療藥):市場預測與分析

Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 301148
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
麥角生物鹼(用作偏頭痛治療藥):市場預測與分析 Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 47 Pages
簡介

麥角生物鹼是市場上第一個供給的偏頭痛特異療法藥物。雖然純麥角生物鹼在1920年第一次被分離出來,但1925年才成功皮下注射治療嚴重難治型偏頭痛(Rothlin, 1955; Stoll, 1965)。這10年來,許多研究員將麥角胺作為偏頭痛治療藥進行各種研究。可使血管收縮的特性強化了研究者對於「偏頭痛的發作是血管造成的」這個假說的確信。

本報告提供偏頭痛治療藥──麥角生物鹼的全球市場相關分析,提供偏頭痛概要和治療方法,競爭的企業·藥品概要,市場競爭概況,藥物的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查
  • 近日出版的相關調查

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 前驅症狀階段
    • 前兆階段
    • 疼痛的階段
    • 後發症狀的階段

第4章 疾病管理

  • 治療方法概要
    • 急性偏頭痛的治療
    • 偏頭痛的預防療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 偏頭痛治療藥的麥角生物鹼

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 未來預測

第7章 附錄

圖表一覽

目錄
Product Code: GDHC373DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

The Ergot Alkaloids were the very first anti-migraine-specific therapy class to reach the market. The first pure ergot alkaloid was isolated in 1920, but only in 1925 was ergotamine used to successfully treat a case of severe and intractable migraine via subcutaneous injection (Rothlin, 1955; Stoll, 1965). Over the following decades, ergotamine's use as a migraine treatment was investigated by various researchers and its potent vasoconstriction properties reinforced the belief that migraine had a vascular origin.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Ergot Alkaloids including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Ergot Alkaloids for the top two countries from 2012 to 2023.
  • Sales information covered for the US and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Ergot Alkaloids performance
  • Obtain sales forecast for Ergot Alkaloids from 2012-2023 in the top two countries (the US and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Ergot Alkaloids

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Migraine Patients
    • 7.4.2. Percent Drug-treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Survey of Prescribing Physicians
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Reviewer
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Product Profile - Ergot Alkaloids
  • Table 7: Ergot Alkaloids SWOT Analysis, 2013
  • Table 8: Global Sales Forecasts ($m) for Ergot Alkaloids, 2012-2023
  • Table 9: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
Back to Top